InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Clayman Michael D., Chief Executive Officer. Officer active across 1 company, notably Flexion Therapeutics Inc. Aggregated, 6 filings have been logged. Activity tracked since 21 June 2021. The latest transaction was filed on 19 November 2021 (Disposition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
335,498 shares@ US$8.5049.8% of flowCommon StockSEC:0001209191-21-065703:0
335,498 shares@ US$8.5049.8% of flowCommon StockSEC:0001209191-21-065703
13,859 sharesCommon StockSEC:0001209191-21-047501
13,859 sharesCommon StockSEC:0001209191-21-047501:0
1,700 shares@ US$7.780.2% of flowCommon StockSEC:0001209191-21-043522
1,700 shares@ US$7.780.2% of flowCommon StockSEC:0001209191-21-043522:0
6 of 6 declarations
About Clayman Michael D.
Michael D. Clayman is the President and Chief Executive Officer of Flexion Therapeutics Inc. He leads the company with a strategic vision focused on innovation and service improvement. His experience in the pharmaceutical sector enables him to guide the company in a constantly evolving environment. He is committed to providing quality solutions to clients.
